



North Texas Institutional Review Board

May 15, 2003

IOMAI
Attn: Gregory Glenn, MD
20 Firstfield Road
#250
Gaithersburg, MD 20878

Re: "Transcutaneous Immunization Using Tetanus Toxoid Non-Absorbed with Heat-Labile Enterotoxin from E. coli as Adjuvant. Study #1." 1998-2000

"Transcutaneous Immunization Using Tetanus Toxoid Non-Absorbed with Heat-Labile Enterotxin from E.coli as Adjuvant. Study #2." 1998-2000

IRB Notice of Intent to Disband and Cease Record Retention


Dear Dr. Glenn:

Our records indicate that the above studies, sponsored by your company, were conducted during the dates indicated above under the authority of the North Texas Institutional Review Board. Our records indicate this research under the NTIRB was completed no later than July 10, 2000. Accordingly, on August 1, 2003 the record keeping period required under 21CFR §§56.115(b) will have expired. On or after that date the NTIRB intends to disband, and records related to these studies in its possession will be destroyed or otherwise handled in accordance with applicable laws and regulations.

If your company wants to obtain these records, then please contact Dr. Neil Dishon, Chief of Staff University of Texas at Arlington **on or before July 1, 2003**. Since Dr. Dishon is now retired, you may contact Mr. Terry Fredeking, President of Antibody Systems, Inc., if you have difficulty in contacting Dr. Dishon. Please see contact information below.

For Dr. Neil Dishon
The University of Texas at Arlington
Health Services
Dr. Neil Dishon, Chief of Staff
605 S. West Street
Arlington, TX 76019
Phone: 817.272.2771
Fax: 817.272.2715

For Mr. Terry Fredeking
Antibody Systems, Inc.
1901 Norwood Drive
Hurst, TX, 76054
Phone: 817.498.8222
Fax: 817.498.8277
Email: tfredeking@antibodysystems.com



Feel free to contact either Dr. Dishon or Mr. Fredeking if there are any questions about the actions to be taken.

Sincerely,

North Texas Institutional Review Board

May 15, 2003

Antibody Systems, Inc.
Attn: Terry M. Fredeking
1901 Norwood Drive
Hurst, TX 76054

Re: "Doxycycline Cytokine Receptors Stimulation." 2000

IRB Notice of Intent to Disband and Cease Record Retention

Dear Mr. Fredeking:

Our records indicate that the above study, sponsored by your company, was conducted during the date indicated above under the authority of the North Texas Institutional Review Board. Our records indicate this research under the NTIRB was completed no later than July 30, 2000. Accordingly, on August 1, 2003 the record keeping period required under 21CFR §§56.115(b) will have expired. On or after that date the NTIRB intends to disband, and records related to this study in its possession will be destroyed or otherwise handled in accordance with applicable laws and regulations.

If your company wants to obtain these records, then please contact Dr. Neil Dishon, Chief of Staff University of Texas at Arlington **on or before July 1, 2003**. Since Dr. Dishon is now retired, you may contact Mr. Terry Fredeking, President of Antibody Systems, Inc., if you have difficulty in contacting Dr. Dishon. Please see contact information below.

For Dr. Neil Dishon

The University of Texas at Arlington
Health Services
Dr. Neil Dishon, Chief of Staff
605 S. West Street
Arlington, TX 76019
Phone: 817.272.2771
Fax: 817.272.2715

For Mr. Terry Fredeking

Antibody Systems, Inc.
1901 Norwood Drive
Hurst, TX, 76054
Phone: 817.498.8222
Fax: 817.498.8277
Email: tfredeking@antibodysystems.com

Feel free to contact either Dr. Dishon or Mr. Fredeking if there are any questions about the actions to be taken.

Sincerely,

North Texas Institutional Review Board

May 15, 2003

Virginia Commonwealth University
Attn: Dr. Adler
P.O. Box 980163
Richmond, VA 23298

Re: "Towne Strain of CMV: A Phase I Study of the Toxicity of
Increasing Doses." 1991-1996

IRB Notice of Intent to Disband and Cease Record Retention

Dear Dr. Adler:

Our records indicate that the above study, sponsored by your company, was conducted during the date indicated above under the authority of the North Texas Institutional Review Board. Our records indicate this research under the NTIRB was completed no later than December 31, 1997. Accordingly, on August 1, 2003 the record keeping period required under 21CFR §§56.115(b) will have expired. On or after that date the NTIRB intends to disband, and records related to this study in its possession will be destroyed or otherwise handled in accordance with applicable laws and regulations.

If your company wants to obtain these records, then please contact Dr. Neil Dishon, Chief of Staff University of Texas at Arlington **on or before July 1, 2003**. Since Dr. Dishon is now retired, you may contact Mr. Terry Fredeking, President of Antibody Systems, Inc., if you have difficulty in contacting Dr. Dishon. Please see contact information below.

For Dr. Neil Dishon

The University of Texas at Arlington
Health Services
Dr. Neil Dishon, Chief of Staff
605 S. West Street
Arlington, TX 76019
Phone: 817.272.2771
Fax: 817.272.2715

For Mr. Terry Fredeking

Antibody Systems, Inc.
1901 Norwood Drive
Hurst, TX, 76054
Phone: 817.498.8222
Fax: 817.498.8277
Email: tfredeking@antibodysystems.com

Feel free to contact either Dr. Dishon or Mr. Fredeking if there are any questions about the actions to be taken.

Sincerely,

North Texas Institutional Review Board

May 15, 2003

Nedra Waelti
Manager Regulatory Affairs - USA & Canada
Berna Biotech Ltd
Rehhagstrasse 79, 3018 Bern, Switzerland
Tel 0041.31.980.6261
Fax 0041.31.980.6213
Email: nedra.waelti@bernabiotech.com

Re: "Production of Hyperimmune Plasma Following Immunization with Pseudomonas Aeruginosa and Klebsiella Vaccines." 1993-1998

"The Study of Safety and Immunogenicity for the production of Hyperimmune Plasma Following Immunization with Escherichia coli O-Polysaccharide: Toxin A Vaccine, Polyvalent." 1993-1998

"Production of Hyperimmune Plasma Following Immunization with Pseudomonas Aeruginosa, Klebsiella, and Escherichia coli Vaccines." 1993-1998

"Production of Hyperimmune Plasma Following Immunization with Rabies Virus vaccine, Inactivated." 1995-1997

"Safety and Immunogenicity of Vivotig Berna L Vaccine Typhoid Vaccine Live Oral Attenuated Ty21a in Healthy Adults." 1997-1999

"Safety and Immunogenicity of Vibrio cholerae CVD 103-HgR in Healthy Adult Volunteers 45-65 Years of Age." 1998-1999

IRB Notice of Intent to Disband and Cease Record Retention

Dear Ms. Waelti:

Our records indicate that the above studies, sponsored by your company, were conducted during the dates indicated above under the authority of the North Texas Institutional Review Board. Our records indicate this research under the NTIRB was completed no later than December 31, 1999. Accordingly, on August 1, 2003 the record keeping period required under 21CFR §§56.115(b) will have expired. On or after that date the NTIRB intends to disband, and records related to these studies in its possession will be destroyed or otherwise handled in accordance with applicable laws and regulations.

If your company wants to obtain these records, then please contact Dr. Neil Dishon, Chief of Staff University of Texas at Arlington **on or before July 1, 2003**. Since Dr. Dishon is now retired, you may contact Mr. Terry Fredeking, President of Antibody Systems, Inc., if you have difficulty in contacting Dr. Dishon. Please see contact information below.

For Dr. Neil Dishon

The University of Texas at Arlington
Health Services
Dr. Neil Dishon, Chief of Staff
605 S. West Street
Arlington, TX 76019
Phone: 817.272.2771
Fax: 817.272.2715

For Mr. Terry Fredeking

Antibody Systems, Inc.
1901 Norwood Drive
Hurst, TX, 76054
Phone: 817.498.8222
Fax: 817.498.8277
Email: tfredeking@antibodysystems.com

Feel free to contact either Dr. Dishon or Mr. Fredeking if there are any questions about the actions to be taken.

Sincerely,

North Texas Institutional Review Board

May 15, 2003

NABI

Attn: Barbara Davies
12280 Wilkins Avenue
Rockville, MD 20852

Re: "Evaluation of the Safety and Immunogenicity of a Staphylococcus aureus Conjugate, Bivalent Vaccine/Immunizing Agent in Plasma Donors and the Identification and Recovery of Immune Source Plasma Targeted Against Staphylococcus aureus." 1994-1996

IRB Notice of Intent to Disband and Cease Record Retention

Dear Ms. Davies:

Our records indicate that the above study, sponsored by your company, was conducted during the date indicated above under the authority of the North Texas Institutional Review Board. Our records indicate this research under the NTIRB was completed no later than December 31, 1996. Accordingly, on August 1, 2003 the record keeping period required under 21CFR §§56.115(b) will have expired. On or after that date the NTIRB intends to disband, and records related to this study in its possession will be destroyed or otherwise handled in accordance with applicable laws and regulations.

If your company wants to obtain these records, then please contact Dr. Neil Dishon, Chief of Staff University of Texas at Arlington **on or before July 1, 2003**. Since Dr. Dishon is now retired, you may contact Mr. Terry Fredeking, President of Antibody Systems, Inc., if you have difficulty in contacting Dr. Dishon. Please see contact information below.

For Dr. Neil Dishon

The University of Texas at Arlington
Health Services
Dr. Neil Dishon, Chief of Staff
605 S. West Street
Arlington, TX 76019
Phone: 817.272.2771
Fax: 817.272.2715

For Mr. Terry Fredeking

Antibody Systems, Inc.
1901 Norwood Drive
Hurst, TX, 76054
Phone: 817.498.8222
Fax: 817.498.8277
Email: tfredeking@antibodysystems.com

Feel free to contact either Dr. Dishon or Mr. Fredeking if there are any questions about the actions to be taken.

Sincerely,

North Texas Institutional Review Board

May 15, 2003

Massachusetts Biologic Laboratories
Attn: Dr. Stanley Cryz
University of Massachusetts Medical School
305 South Street
Jamaica Plain, MA 02130

Re: "Production of Hyperimmune plasma Following Immunization with
Pertussis Toxoid Vaccine." 1990-1993

IRB Notice of Intent to Disband and Cease Record Retention

Dear Dr. Cryz:

Our records indicate that the above study, sponsored by your company, was conducted during the date indicated above under the authority of the North Texas Institutional Review Board. Our records indicate this research under the NTIRB was completed no later than December 31, 1993. Accordingly, on August 1, 2003 the record keeping period required under 21CFR §§56.115(b) will have expired. On or after that date the NTIRB intends to disband, and records related to this study in its possession will be destroyed or otherwise handled in accordance with applicable laws and regulations.

If your company wants to obtain these records, then please contact Dr. Neil Dishon, Chief of Staff University of Texas at Arlington **on or before July 1, 2003**. Since Dr. Dishon is now retired, you may contact Mr. Terry Fredeking, President of Antibody Systems, Inc., if you have difficulty in contacting Dr. Dishon. Please see contact information below.

For Dr. Neil Dishon

The University of Texas at Arlington
Health Services
Dr. Neil Dishon, Chief of Staff
605 S. West Street
Arlington, TX 76019
Phone: 817.272.2771
Fax: 817.272.2715

For Mr. Terry Fredeking

Antibody Systems, Inc.
1901 Norwood Drive
Hurst, TX, 76054
Phone: 817.498.8222
Fax: 817.498.8277
Email: tfredeking@antibodysystems.com

Feel free to contact either Dr. Dishon or Mr. Fredeking if there are any questions about the actions to be taken.

Sincerely,

North Texas Institutional Review Board

May 15, 2003

Antibody Systems, Inc.
Attn: Mr. Terry Fredeking
1901 Norwood Drive
Hurst, TX 76054

Re: "Collection of Source Plasma that Contains Antibodies to Trypanosoma cruzi." No research done.

IRB Notice of Intent to Disband and Cease Record Retention

Dear Mr. Fredeking

Our records indicate that the above study, sponsored by your company, was conducted during the date indicated above under the authority of the North Texas Institutional Review Board. Our records indicate there was no research done on this project. Accordingly, on August 1, 2003 the record keeping period required under 21CFR §§56.115(b) will have expired. On or after that date the NTIRB intends to disband, and records related to this study in its possession will be destroyed or otherwise handled in accordance with applicable laws and regulations.

If your company wants to obtain these records, then please contact Dr. Neil Dishon, Chief of Staff University of Texas at Arlington **on or before July 1, 2003**. Since Dr. Dishon is now retired, you may contact Mr. Terry Fredeking, President of Antibody Systems, Inc., if you have difficulty in contacting Dr. Dishon. Please see contact information below.

For Dr. Neil Dishon

The University of Texas at Arlington
Health Services
Dr. Neil Dishon, Chief of Staff
605 S. West Street
Arlington, TX 76019
Phone: 817.272.2771
Fax: 817.272.2715

For Mr. Terry Fredeking

Antibody Systems, Inc.
1901 Norwood Drive
Hurst, TX, 76054
Phone: 817.498.8222
Fax: 817.498.8277
Email: tfredeking@antibodysystems.com

Feel free to contact either Dr. Dishon or Mr. Fredeking if there are any questions about the actions to be taken.

Sincerely,
